Objective To explore the clinical effect of Shenyan Kangfu Tablets combined with Empagliflozin Tablets in treatment of diabetic nephropathy.Methods Patients(70 cases)with diabetic nephropathy admitted to the outpatient department of Tianjin Hospital from July 2022 to November 2023 were selected and divided into control group and treatment group by random table method,with 35 cases in each group.Patients in control group were po Empagliflozin Tablets on an empty stomach,10 mg/time,once daily.Patients in the treatment group were po Shenyan Kangfu Tablets on the basis of control group,5 tablets/time,3 times daily.Both groups were treated for 12 weeks.The clinical efficacy,glucose metabolism index,renal function index,and serum inflammation index were compared between two groups.Results After treatment,the total effective rates of the control group and the treatment group were 71.42%and 88.57%,and the difference between two groups was statistically significant(P<0.05).After treatment,FPG and HbA1c in two groups were significantly decreased(P<0.05),and there was no significant difference in FPG and HbA1c between two groups.After treatment,BUN,Scr,and UACR in two groups were lower than before(P<0.05),and BUN,Scr,and UACR in the treatment group were lower than those in the control group(P<0.05).After treatment,the serum levels of TGF-β1 and TNF-α were decreased in two groups(P<0.05),and the serum levels of TGF-β1 and TNF-α in the treatment group were lower than those in the control group(P<0.05).Conclusion Shenyan Kangfu Tablets combined with Empagliflozin Tablets in treatment of diabetic nephropathy can improve the clinical effect,improve the level of blood sugar,protect kidney,and reduce the inflammatory response.
NETL
NSTL
万方数据
